In fiscal year 2025, MYUNGIN PHARM (317450) reported revenue of 287.3 billion KRW.
Income Statement
| Year | Revenue | Op Profit | Net Income | Source |
|---|---|---|---|---|
| 2025 | 287.3 billion KRW | 92.5 billion KRW | 81.4 billion KRW | [source] |
| 2024 | 269.4 billion KRW | 92.8 billion KRW | 68.7 billion KRW | — |
| 2023 | 242.3 billion KRW | 83.6 billion KRW | 74.5 billion KRW | — |
Balance Sheet
| Year | Total Assets | Total Liabilities | Total Equity | Source |
|---|---|---|---|---|
| 2025 | 831.5 billion KRW | 48.4 billion KRW | 783.1 billion KRW | [source] |
| 2024 | — | — | — | — |
| 2023 | — | — | — | — |
Years without a source link are outside the DART financial API collection period.
Balance sheet figures for the relevant year were not collected.